James Samuel Shannon - Jun 16, 2025 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: Director
Signature: /s/ Kevin Brennan, Attorney-in-Fact
Stock symbol: XLO
Transactions as of: Jun 16, 2025
Transactions value $: $48,085
Form type: 4
Date filed: 6/18/2025, 04:57 PM
Previous filing: Jun 12, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shannon James Samuel	Director	828 WINTER STREET, SUITE 300, WALTHAM	/s/ Kevin Brennan, Attorney-in-Fact	2025-06-18	0001485417

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XLO	Common Stock	Purchase	$30.9K	+45K		$0.69	45K	Jun 16, 2025	Direct	F1
transaction	XLO	Common Stock	Purchase	$17.2K	+25K	+55.56%	$0.69	70K	Jun 17, 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6799 to $0.6891 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6659 to $0.6991 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6799 to $0.6891 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6659 to $0.6991 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.